We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Ken has been leading the Therapy Acceleration Program (TAP) at the Leukemia & Lymphoma Society. Ken is responsible for the venture philanthropy arm of LLS; investing in promising blood cancer assets from academia and biotech. Currently the TAP portfolio has 20 assets and Ken has been part of recent deals including early programs from biotech. TAP is part of Research at LLS and its purpose is to fund projects related to therapies or diagnostics that have the potential to change the standard of care for patients with blood cancers. Within its 10 year history, TAP has two successful FDA approved assets: Celator Pharmaceuticals (now Jazz Pharmaceuticals) with Vyxeos for AML and Kite Pharma (now Gilead Sciences) with Yescarta for NHL.
This speaker's sessions: